ESMO Symposium on Immuno-Oncology 2015

Oncology Meeting Resources

20 Nov - 21 Nov, Lausanne, Switzerland


There is a paradigm shift in the treatment of cancer with recent research demonstrating that the immune system has tremendous potential to destroy tumours. Is immuno-oncology the new era of cancer medicine? 

Abstracts, presentations and webcasts from the ESMO Symposium on Immuno-Oncology 2015 are now available here to ESMO members. The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.

Useful Links

Presenter Presentation title Session title
Rolf A. Stahel Welcome to the Symposium Welcome session
Gordon Freeman Checkpoint inhibition: a perspective and a glimpse into the future Checkpoint inhibition: A perspective and a glimpse into the future
Matthew Hellman Response to PD1 blockade capitalises on cancer neo-antigens Cancer neo-antigens
David Feltquate PD-1 Blockade: Improving survival for patients across several tumour types PD-1/PD-L1 axis blockade, results to date
Gregory Lubiniecki Correlation of PD-L1 expression and tumour outcomes in NSCLC patients PD-1/PD-L1 axis blockade, results to date
Ramy Ibrahim Monotherapy and combinations: Opportunities anchored on PD-L1 blockade PD-1/PD-L1 axis blockade, results to date
William Grossman Oncology meets immunology: Towards the future for personalised cancer immunotherapy PD-1/PD-L1 axis blockade, results to date
Michele Maio Combinations with epigenetic therapy Immuno-oncology meets molecular oncology
Zane Yang 1PD - Immunotherapy with INO-3112 (HPV16 and HPV18 plasmids + IL-12 DNA) in human papillomavirus (HPV) associated head and neck squamous cell carcinoma (HNSCCa) Poster Discussion session
Suvi Parviainen 2PD - Oncolytic adenoviruses armed with TNFα and IL-2 enable successful adoptive T-cell therapy of solid tumors Poster Discussion session
Aung Naing 3PD - PEGylated human IL-10 (AM0010) in advanced solid tumors Poster Discussion session
Sébastien Wälchli 4PD - A universal killer T-cell for adoptive cell therapy of cancer Poster Discussion session
nicolas Mach 5PD - Cell-based immunotherapy combining encapsulation cell technology and irradiated autologous tumor cells: A novel technology platform that is both safe and feasible. Results from first in man trial Poster Discussion session
Denis Migliorini 6PD - Phase I/II study of IMA950 peptide vaccine with Poly-ICLC in combination with standard therapy in newly diagnosed A2 glioblastoma: Preliminary results Poster Discussion session
Nikolaos Pistamaltzian 7PD - Preexisting immunity as a potential biomarker for clinical response to AE37 vaccination in breast cancer patients Poster Discussion session